Margaret (Margi) McLoughlin, Ph.D., joined Quince Therapeutics’ Board of Directors in December 2015. Until April of 2019, Dr. McLoughlin worked in Pfizer’s Worldwide Business Development (WWBD) organization and Pfizer Ventures where she was a Partner in Pfizer Ventures and an Executive Director in WWBD. In this role, she served on the boards of 4D Molecular Therapeutics, Adapsyn, BioAtla, System1, and Quince Therapeutics with a focus on making investments and working with companies to help advance products and technologies of value to the pharmaceutical industry. After joining Pfizer in 2001, Dr. McLoughlin worked in roles of increasing responsibility in WWBD, played a significant role in defining Pfizer’s Centers for Therapeutic Innovation, in addition to leading transactions with multiple biotech companies, including Ablexis, Gliknik, and Excaliard, among others. She also held a position in Discovery Research at Mallinckrodt Medical developing diagnostic pharmaceuticals for nuclear medicine, MR, and X-ray imaging. After five years in the laboratory, Dr. McLoughlin spent two years in Technology Planning at Mallinckrodt Medical where she supported internal R&D through outside alliances. Additionally, she served as Associate Director in the Office of Cooperative Research at Yale University. Dr. McLoughlin holds a B.S. in Chemistry from University of California, Irvine and a Ph.D. in Chemistry from University of California, Santa Barbara.